Biologic targeted therapy in allergic asthma

Annals of Allergy, Asthma and Immunology

Volumn 112, Issue 2, 2014, Pages 108-115

  Bice, Jeffrey B ^a   Leechawengwongs, Evelyn ^b   Montanaro, Anthony ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALTRAKINCEPT; AMG 317; ANRUKINZUMAB; BENRALIZUMAB; CINQUIL; ETANERCEPT; GOLIMUMAB; IMIQUIMOD; IMMUNOGLOBULIN E; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PASCOLIZUMAB; PITRAKINRA; PLACEBO; QBG 10; RESIQUIMOD; RESLIZUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDUPIPRANT;

ADD ON THERAPY; ALLERGIC ASTHMA; ANAPHYLAXIS; BIOLOGICAL THERAPY; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENOTYPE; HISTORY; HUMAN; IMMUNOGLOBULIN PRODUCTION; INJECTION SITE REACTION; MALIGNANT NEOPLASTIC DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SEPSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SORE THROAT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULIN E; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; MOLECULAR TARGETED THERAPY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN-4; RECEPTORS, PROSTAGLANDIN; RESPIRATORY HYPERSENSITIVITY; TH2 CELLS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893124137     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.12.013     Document Type: Review

References (78)

1. S. Eisenberg Biologic therapy J Infus Nurs 35 2012 301 313
2. A.P. Kaplan, K. Joseph, R.J. Maykut, G.P. Geba, and R.K. Zeldin Treatment of chronic autoimmune urticaria with omalizumab J Allergy Clin Immunol 122 2008 569 573
3. S.T. Holgate Stratified approaches to the treatment of asthma Br J Clin Pharmacol 76 2013 277 291
4. M. Hoshino, and J. Ohtawa Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma Respiration 83 2012 520 528
5. A.M. Riccio, R.W. Dal Negro, and C. Micheletto et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients Int J Immunopathol Pharmacol 25 2012 475 484
6. Y.-C. Huang, B. Leyko, and M. Frieri Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells Ann Allergy Asthma Immunol 95 2005 443 451
7. Z. Zietkowski, R. Skiepko, M.M. Tomasiak-Lozowska, and A. Bodzenta-Lukaszyk Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma Respiration 80 2010 534 542
8. G. Pelaia, A. Vatrella, and R. Maselli The potential of biologics for the treatment of asthma Nat Rev Drug Discov 11 2012 958 972
9. M. Humbert, R. Beasley, and J. Ayres et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
10. N.A. Hanania, S. Wenzel, and K. Rosén et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
11. M. Molimard, F. De Blay, A. Didier, and V. Le Gros Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France Respir Med 102 2008 71 76
12. L. Cox, T.A. Platts-Mills, and I. Finegold et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis J Allergy Clin Immunol 128 2007 210 212
13. G.J. Rodrigo, H. Neffen, and J.A. Castro-Rodriguez Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review Chest 139 2011 28 35
14. T. Machino, S. Hashimoto, and Y. Gon et al. Interleukin-4 and interleukin-13 induce fibronectin production by human lung fibroblasts Allergol Int 50 2001 197 202
15. T.K. Hart, R.M. Cook, and P. Zia-Amirhosseini et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys J Allergy Clin Immunol 108 2001 250 257
16. T.K. Hart, M.N. Blackburn, and M. Brigham-Burke et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma Clin Exp Immunol 130 2002 93 100
17. R.S. Shames, V. Vexler, and N.M. Lane The safety and pharmacokinetics of SB240683 (anti-Il-4 humanized monoclonal antibody) in patients with mild to moderate asthma J Allergy Clin Immunol 107 2001 1030
18. S. Wenzel, D. Wilbraham, R. Fuller, E.B. Getz, and M. Longphre Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370 2007 1422 1431
19. W.R. Henderson, E.Y. Chi, and C.R. Maliszewski Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma J Immunol 164 2000 1086 1095
20. L. Borish, H. Nelson, and M.J. Lanz et al. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized, placebo-controlled trial Am J Respir Crit Care Med 160 1999 1816 1823
21. L.C. Borish, H.S. Nelson, and J. Corren et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma J Allergy Clin Immunol 107 2001 963 970
22. D. Desai, and C. Brightling Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol 158 2009 10 19
23. S. Wenzel, L. Ford, and D. Pearlman et al. Dupilumab in persistent asthma with elevated eosinophil levels N Engl J Med 368 2013 2455 2466
24. Z. Zhu, R.J. Homer, and Z. Wang et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production J Clin Invest 103 1999 779 788
25. M. Ultsch, J. Bevers, and G. Nakamura et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab J Mol Biol 425 2013 1330 1339
26. T.C. Kotsimbos, P. Ernst, and Q.A. Hamid Interleukin-13 and interleukin-4 are coexpressed in atopic asthma Proc Assoc Am Phys 108 1996 368 373
27. S.K. Saha, M.A. Berry, and D. Parker et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma J Allergy Clin Immunol 121 2008 685 691
28. P.G. Woodruff, B. Modrek, and D.F. Choy et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 2009 388 395
29. G. Grünig, D.B. Corry, J. Reibman, and M. Wills-Karp Interleukin 13 and the evolution of asthma therapy Am J Clin Exp Immunol 1 2012 20 27
30. G. Jia, R.W. Erickson, and D.F. Choy et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients J Allergy Clin Immunol 130 2012 647 654
31. T. Naseer, E.M. Minshall, and D.Y. Leung et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy Am J Respir Crit Care Med 155 1997 845 851
32. J. Corren, R.F. Lemanske, and N.A. Hanania et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
33. M. Noonan, P. Korenblat, and S. Mosesova et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids J Allergy Clin Immunol 132 2013 567 574.e12
34. C. Blanchard, A. Mishra, H. Saito-Akei, P. Monk, I. Anderson, and M.E. Rothenberg Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354) Clin Exp Allergy 35 2005 1096 1103
35. E. Piper, C. Brightling, and R. Niven et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Eur Respir J 41 2013 330 338
36. M.T. Kasaian, D. Raible, and K. Marquette et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2 J Immunol 187 2011 561 569
37. M.T. Kasaian, D.D. Donaldson, and L. Tchistiakova et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma Am J Respir Cell Mol Biol 36 2007 368 376
38. G.M. Gauvreau, L.P. Boulet, and D.W. Cockcroft et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma Am J Respir Crit Care Med 183 2011 1007 1014
39. R. Leigh, D. Vethenayagam, and M. Yoshida et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma Am J Respir Crit Care Med 166 2002 1212 1217
40. R.G. Stirling, E.L. Van Rensen, P.J. Barnes, and K.F. Chung Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma Am J Respir Crit Care Med 164 2001 1403 1409
41. Q. Hamid, M. Azzawi, and S. Ying et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma J Clin Invest 87 1991 1541 1546
42. M. Humbert, C.J. Corrigan, P. Kimmitt, S.J. Till, A.B. Kay, and S.R. Durham Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma Am J Respir Crit Care Med 156 1997 704 708
43. D. Robinson, Q. Hamid, and S. Yng et al. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression Am Rev Respir Dis 148 1993 401 406
44. C.G. Garlisi, T.T. Kung, and P. Wang et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation Am J Respir Cell Mol Biol 20 1999 248 255
45. P.J. Mauser, A.M. Pitman, and X. Fernandez et al. Effects of an antibody to interleukin-5 in a monkey model of asthma Am J Respir Crit Care Med 152 1995 467 472
46. M.J. Leckie, A. ten Brinke, and J. Khan et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
47. P. Flood-Page, C. Swenson, and I. Faiferman et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
48. P. Haldar, C.E. Brighling, and B. Hargadon et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
49. P. Nair, M.M. Pizzichini, and M. Kjarsgaard et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
50. I. Pavord, S. Korn, and P. Howarth et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
51. Y. Liu, S. Zhang, D. Li, and S. Jiang Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials PloS One 8 2013 e59872
52. W.J. Cook, L.J. Walter, and N.J. Murgolo et al. Structure and humanization of a rat monoclonal Fab to human interleukin-5 Protein Eng 9 1996 623 628
53. M. Castro, S. Mathur, and F. Hargreave et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study Am J Respir Crit Care Med 184 2011 1125 1132
54. M.E. Wechsler, P.E. Fulkerson, and B.S. Bochner et al. Novel targeted therapies for eosinophilic disorders J Allergy Clin Immunol 130 2012 563 571
55. W.W. Busse, R. Katial, and D. Gossage et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma J Allergy Clin Immunol 125 2010 1237 1244.e2
56. A. Ghazi, A. Trikha, and W.J. Calhoun Benralizumab-a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity-a novel approach for the treatment of asthma Expert Opin Biol Ther 12 2012 113 118
57. M.A. Lokuta, and A. Huttenlocher TNF-alpha promotes a stop signal that inhibits neutrophil polarization and migration via a p38 MAPK pathway J Leukocyte Biol 78 2005 210 219
58. M.A. Berry, B. Hargadon, and M. Shelley et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma N Engl J Med 354 2006 697 708
59. P.H. Howarth, K.S. Babu, and A.S. Arshad et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma Thorax 60 2005 1012 1018
60. J.B. Morjaria, A.J. Chauhan, K.S. Babu, R. Polosa, D.E. Davies, and S.T. Holgate The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial Thorax 63 2008 584 591
61. E.M. Erin, B.R. Leaker, and G.C. Nicholson et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma Am J Respir Crit Care Med 174 2006 753 762
62. S.E. Wenzel, P.J. Barnes, and E.R. Bleecker et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma Am J Respir Crit Care Med 179 2009 549 558
63. W.W. Busse, S.E. Wenzel, and E.O. Meltzer et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients J Allergy Clin Immunol 131 2013 339 345
64. N. Barnes, I. Pavord, and A. Chuchalin et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma Clin Exp Allergy 42 2012 38 48
65. A. Straumann, S. Hoesli, and C. Bussmann et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis Allergy 68 2013 375 385
66. K.M. Beeh, F. Kanneiss, and F. Wagner et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma J Allergy Clin Immunol 131 2013 866 874
67. E.H. Kaufman, A.D. Fryer, and D.B. Jacoby Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs J Allergy Clin Immunol 127 2011 462 469
68. M. Biffen, H. Matsui, and S. Edwards et al. Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity Br J Pharmacol 166 2012 573 586
69. P.J. Pockros, D. Guyader, and H. Patton et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies J Hepatol 47 2007 174 182
70. S.J. Szefler, S. Wenzel, and R. Brown et al. Asthma outcomes: biomarkers J Allergy Clin Immunol 129 2012 S9 S23
71. J.L. Ingram, and M. Kraft IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies J Allergy Clin Immunol 130 2012 829 844
72. S.E. Wenzel Tissue-based and bronchoalveolar lavage-based biomarkers in asthma Immunol Allergy Clin North Am 32 2012 401 411
73. S.E. Wenzel Asthma phenotypes: the evolution from clinical to molecular approaches Nat Med 18 2012 716 725
74. J.D. Spahn Asthma biomarkers in sputum Immunol Allergy Clin North Am 32 2012 387 399
75. H.L. Petsky, C.J. Cates, and T.J. Lasserson et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils) Thorax 67 2012 199 208
76. E.H. Kaufman, A.D. Fryer, and D.B. Jacoby Toll-like receptor 7 agonists are potent and rapid bronchodilators in guinea pigs J Allergy Clin Immunol 127 2011 462 469
77. M. Biffen, H. Matsui, and S. Edwards et al. Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity Br J Pharmacol 166 2012 573 586
78. Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46:324-329.